Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5)
|癌におけるオーダーメイド医療：医師レベルにおける主な促進因子・課題の評価 (EU5ヶ国) Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5)|
|出版日: 2015年05月01日||ページ情報: 英文||
当レポートでは、EU5ヶ国 (フランス、ドイツ、スペイン、イタリアおよび英国) の癌専門医150人を対象に実施した調査の結果に基づき、癌専門医が考えるオーダーメイド医療の分野における重要な問題、課題および機会について考察し、癌専門医は将来どのようなオーダーメイド医療の導入を意図しているのか、調査しています。
Gain exclusive insights on the perceived value and benefits of personalised medicine and on the key challenges and opportunities in relation to implementation from treating oncologists.
Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5) is based on survey results from 150 oncologists (104 medical oncologists and 46 haematologist-oncologists) in France, Germany, Spain, Italy and the UKand offers insights on what oncologists believe are the critical issues, challenges and opportunities within the personalised medicines space, and how oncologists intend to adopt personalised medicine in the future.
A great deal of anticipation and expectation surrounds personalised medicine. While there have been some notable successes, the promise of personalised medicine - right medicine, right patient, right time - has failed to materialise in many disease areas where a personalised approach could drive better patient outcomes. Concerns amongst key stakeholder groups remain, particularly in relation to development, access and implementation of personalised healthcare strategies.
This survey provides EU5 physician insights into personalised medicine within the oncology setting. By understanding what oncologists in the major markets in Europe think about the key challenges, opportunities and concerns, companies operating in the oncology market and seeking to leverage personalised medicine for their products can gain a deep understanding of what's needed to drive long-term commercial success.
Filled with charts and up-to-the-minute survey analysis, this report offers: